Cordis/Volcano
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Cordis will promote Volcano's intravascular ultrasound technology alongside its Cypher drug-eluting stents in Europe under a non-exclusive collaboration announced Nov. 8. Currently, only 3.5% of percutaneous coronary interventions performed in Europe use IVUS imaging technology to guide stent placement. Volcano and Johnson & Johnson are also both cosponsors of the ADAPT-DES study, which will enroll from 11,000 to 15,000 patients, including 3,000 patients who will be imaged with Volcano's Eagle Eye Gold IVUS catheter during initial drug-eluting stent placement and in follow-up assessments of dual antiplatelet therapy (1"The Gray Sheet" Oct. 29, 2007, p. 8)